康希诺生物 CanSinoBIO

Keywords you search：

1 Form of Proxy for use at the 2024 First Extraordinary General Meeting to be held on Wednesday, February 21, 2024

Description
2 2024 FIRST EGM CIRCULAR

Description
3 VOLUNTARY ANNOUNCEMENT OBTAINING THE FINAL REPORT OF PHASE III CLINICAL TRIAL OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (CRM197, TT VECTOR)

Description
4 INSIDE INFORMATION RESULTS FORECAST FOR THE YEAR 2023

Description
5 Monthly Return of Equity Issuer on Movements in Securities

Description
6 INSIDE INFORMATION DECONSOLIDATION OF CANSINO SPH BIOLOGICS INC.

Description
7 FURTHER ELABORATION OF CUMULATIVE VOTING SYSTEM TO BE ADOPTED FOR CERTAIN RESOLUTIONS PROPOSED AT THE 2024 FIRST EGM

Description
8 POLL RESULTS OF THE 2024 FIRST EXTRAORDINARY GENERAL MEETING

Description
9 List of Directors and their Roles and Functions

Description
10 Articles of Association

Description

First Page Pre. Page Current Page(57) Next Page End Page(62)